-
3
-
-
65349177540
-
-
Jawed I, Lee CM, Tward JD, et al. Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis. (#8019). J Clin Oncol, 2007. ASCO Annual Meeting Proceedings. No. 18S (June 20 Supplement). 2007;25 Part I.
-
Jawed I, Lee CM, Tward JD, et al. Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis. (#8019). J Clin Oncol, 2007. ASCO Annual Meeting Proceedings. No. 18S (June 20 Supplement). 2007;25 Part I.
-
-
-
-
4
-
-
26844556860
-
Multiple myeloma in elderly patients: Prognostic factors and outcome
-
Anagnostopoulos A, Gika D, Symeonidis A, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol. 2005;75:370-5.
-
(2005)
Eur J Haematol
, vol.75
, pp. 370-375
-
-
Anagnostopoulos, A.1
Gika, D.2
Symeonidis, A.3
-
5
-
-
43249125513
-
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group
-
Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111:4039-47.
-
(2008)
Blood
, vol.111
, pp. 4039-4047
-
-
Ludwig, H.1
Durie, B.G.2
Bolejack, V.3
-
7
-
-
8944220233
-
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
-
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-7.
-
(1996)
N Engl J Med
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
-
8
-
-
0034791513
-
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
-
Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600-7.
-
(2001)
Br J Haematol
, vol.114
, pp. 600-607
-
-
Badros, A.1
Barlogie, B.2
Siegel, E.3
-
9
-
-
32844467928
-
Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: A nation-wide analysis
-
Jantunen E, Itala M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant. 2006;37:367-72.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 367-372
-
-
Jantunen, E.1
Itala, M.2
Juvonen, E.3
-
10
-
-
0014661330
-
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens
-
Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680-5.
-
(1969)
JAMA
, vol.208
, pp. 1680-1685
-
-
Alexanian, R.1
Haut, A.2
Khan, A.U.3
-
12
-
-
32644438680
-
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
-
Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107:1292-8.
-
(2006)
Blood
, vol.107
, pp. 1292-1298
-
-
Facon, T.1
Mary, J.Y.2
Pegourie, B.3
-
13
-
-
0344076348
-
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group
-
Group MTC
-
Group MTC. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16:3832-42.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3832-3842
-
-
-
14
-
-
0026656725
-
Primary dexamethasone treatment of multiple myeloma
-
Alexanian R, Dimopoulos MA, Delasalle K, et al. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887-90.
-
(1992)
Blood
, vol.80
, pp. 887-890
-
-
Alexanian, R.1
Dimopoulos, M.A.2
Delasalle, K.3
-
15
-
-
5644267858
-
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma
-
Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127:159-64.
-
(2004)
Br J Haematol
, vol.127
, pp. 159-164
-
-
Hernandez, J.M.1
Garcia-Sanz, R.2
Golvano, E.3
-
16
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
-
17
-
-
25144435821
-
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
-
Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428-33.
-
(2005)
Cancer
, vol.104
, pp. 1428-1433
-
-
Palumbo, A.1
Bertola, A.2
Musto, P.3
-
18
-
-
33644843725
-
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial
-
Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-31.
-
(2006)
Lancet
, vol.367
, pp. 825-831
-
-
Palumbo, A.1
Bringhen, S.2
Caravita, T.3
-
19
-
-
34848833957
-
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial
-
Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-18.
-
(2007)
Lancet
, vol.370
, pp. 1209-1218
-
-
Facon, T.1
Mary, J.Y.2
Hulin, C.3
-
20
-
-
54049135250
-
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial
-
DOI 10.1182/blood-2008-04-149427
-
Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood. 2008; DOI 10.1182/blood-2008-04-149427.
-
(2008)
Blood
-
-
Palumbo, A.1
Bringhen, S.2
Liberati, A.M.3
-
21
-
-
41349085289
-
Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01
-
Hulin C, Facon T, Rodon P, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood. 2007;110.
-
(2007)
Blood
, pp. 110
-
-
Hulin, C.1
Facon, T.2
Rodon, P.3
-
22
-
-
51049089645
-
Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: A placebo controlled randomised phase 3 trial
-
Waage A, Gimsing P, Juliusson G, et al. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. Blood. 2008;110.
-
(2008)
Blood
, pp. 110
-
-
Waage, A.1
Gimsing, P.2
Juliusson, G.3
-
23
-
-
65349177539
-
-
Wijermans P, Schaafsma P, Van Norden Y, et al. Melphalan Prednisone versus Melphalan Prednisone Thalidomide in induction therapy for Multiple Myeloma in Elderly patients: First interim results of the Dutch cooperative group HOVON. (#0440). Haematologica. 2008;93(s1):178.
-
Wijermans P, Schaafsma P, Van Norden Y, et al. Melphalan Prednisone versus Melphalan Prednisone Thalidomide in induction therapy for Multiple Myeloma in Elderly patients: First interim results of the Dutch cooperative group HOVON. (#0440). Haematologica. 2008;93(s1):178.
-
-
-
-
24
-
-
43249097561
-
Thalidomide for treatment of multiple myeloma: 10 years later
-
Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968-77.
-
(2008)
Blood
, vol.111
, pp. 3968-3977
-
-
Palumbo, A.1
Facon, T.2
Sonneveld, P.3
-
25
-
-
39149109289
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
-
Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-23.
-
(2008)
Leukemia
, vol.22
, pp. 414-423
-
-
Palumbo, A.1
Rajkumar, S.V.2
Dimopoulos, M.A.3
-
26
-
-
42149083845
-
High-dose melphalan-based autotransplants for multiple myeloma: The Arkansas experience since 1989 in 3077 patients
-
Pineda-Roman M, Barlogie B, Anaissie E, et al. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008;112:1754-64.
-
(2008)
Cancer
, vol.112
, pp. 1754-1764
-
-
Pineda-Roman, M.1
Barlogie, B.2
Anaissie, E.3
-
28
-
-
0037291745
-
Thalidomide: A review of approved and investigational uses
-
Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003;25:342-95.
-
(2003)
Clin Ther
, vol.25
, pp. 342-395
-
-
Matthews, S.J.1
McCoy, C.2
-
29
-
-
10744230613
-
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
-
Ghobrial IM, Dispenzieri A, Bundy KL, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant. 2003;32:587-92.
-
(2003)
Bone Marrow Transplant
, vol.32
, pp. 587-592
-
-
Ghobrial, I.M.1
Dispenzieri, A.2
Bundy, K.L.3
-
30
-
-
0035880229
-
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identifi cation of prognostic factors in a phase 2 study of 169 patients
-
Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identifi cation of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-4.
-
(2001)
Blood
, vol.98
, pp. 492-494
-
-
Barlogie, B.1
Desikan, R.2
Eddlemon, P.3
-
31
-
-
0036843032
-
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
-
Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-23.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4319-4323
-
-
Rajkumar, S.V.1
Hayman, S.2
Gertz, M.A.3
-
32
-
-
0037103292
-
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy
-
Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-71.
-
(2002)
Blood
, vol.100
, pp. 1168-1171
-
-
Zangari, M.1
Siegel, E.2
Barlogie, B.3
-
33
-
-
0035469858
-
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
-
Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-58.
-
(2001)
Blood
, vol.98
, pp. 1614-1658
-
-
Zangari, M.1
Anaissie, E.2
Barlogie, B.3
-
34
-
-
2942748363
-
Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study
-
Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology. 2004;62:2291-3.
-
(2004)
Neurology
, vol.62
, pp. 2291-2293
-
-
Cavaletti, G.1
Beronio, A.2
Reni, L.3
-
35
-
-
3042735765
-
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of effi cacy, toxicity, and biological activity
-
Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of effi cacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79:875-82.
-
(2004)
Mayo Clin Proc
, vol.79
, pp. 875-882
-
-
Richardson, P.1
Schlossman, R.2
Jagannath, S.3
-
36
-
-
33749051832
-
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
-
Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507-14.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4507-4514
-
-
Mileshkin, L.1
Stark, R.2
Day, B.3
-
37
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-17.
-
(2003)
N Engl J Med
, vol.348
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
-
38
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-98.
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
-
39
-
-
0037443551
-
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications
-
Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-80.
-
(2003)
Blood
, vol.101
, pp. 2377-2380
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Richardson, P.G.3
-
40
-
-
33644916110
-
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
-
Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24:937-44.
-
(2006)
J Clin Oncol
, vol.24
, pp. 937-944
-
-
Berenson, J.R.1
Yang, H.H.2
Sadler, K.3
-
41
-
-
33748287079
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase I/II study
-
Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood. 2006; 108:2165-72.
-
(2006)
Blood
, vol.108
, pp. 2165-2172
-
-
Mateos, M.V.1
Hernandez, J.M.2
Hernandez, M.T.3
-
42
-
-
42149176608
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
-
Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93:560-5.
-
(2008)
Haematologica
, vol.93
, pp. 560-565
-
-
Mateos, M.V.1
Hernandez, J.M.2
Hernandez, M.T.3
-
43
-
-
41349101245
-
MMY-3002: A Phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma
-
San Miguel J, Schlag R, Khuageva N, et al. MMY-3002: A Phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood. 2007;110.
-
(2007)
Blood
, pp. 110
-
-
San Miguel, J.1
Schlag, R.2
Khuageva, N.3
-
44
-
-
4344641976
-
Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma
-
Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol. 2004;22:3212-4.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3212-3214
-
-
Richardson, P.1
Anderson, K.2
-
45
-
-
0037097595
-
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications
-
Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-30.
-
(2002)
Blood
, vol.99
, pp. 4525-4530
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Poulaki, V.3
-
46
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-7.
-
(2002)
Blood
, vol.100
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
-
47
-
-
21344450660
-
Combination therapy with CC-5013 (Lenalidomide, RevlimidTM) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM)
-
Rajkumar SV, Hayman S, Lacy MQ, et al. Combination therapy with CC-5013 (Lenalidomide, RevlimidTM) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood. 2004;104:98a.
-
(2004)
Blood
, vol.104
-
-
Rajkumar, S.V.1
Hayman, S.2
Lacy, M.Q.3
-
48
-
-
33847345069
-
Oral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter phase I/II study
-
Palumbo A, Falco P, Falcone A, et al. Oral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood. 2007;108.
-
(2007)
Blood
, pp. 108
-
-
Palumbo, A.1
Falco, P.2
Falcone, A.3
-
49
-
-
33644831033
-
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group
-
Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-6.
-
(2006)
J Clin Oncol
, vol.24
, pp. 431-436
-
-
Rajkumar, S.V.1
Blood, E.2
Vesole, D.3
-
50
-
-
51049103084
-
Thalidomide-dexamethasone vs melphalan-prednisone as first line treatment and thalidomide-interferon vs interferon maintenance therapy in elderly patients with multiple myeloma
-
Ludwig H, Tothova E, Hajek R, et al. Thalidomide-dexamethasone vs melphalan-prednisone as first line treatment and thalidomide-interferon vs interferon maintenance therapy in elderly patients with multiple myeloma. Blood. 2007;110.
-
(2007)
Blood
, pp. 110
-
-
Ludwig, H.1
Tothova, E.2
Hajek, R.3
-
51
-
-
32544447241
-
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/ refractory multiple myeloma: A prospective, multicenter, phase II study
-
Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/ refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91:133-6.
-
(2006)
Haematologica
, vol.91
, pp. 133-136
-
-
Offidani, M.1
Corvatta, L.2
Marconi, M.3
-
52
-
-
21344459018
-
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
-
Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129:763-70.
-
(2005)
Br J Haematol
, vol.129
, pp. 763-770
-
-
Kyriakou, C.1
Thomson, K.2
D'Sa, S.3
-
53
-
-
0035018156
-
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
-
Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399-403.
-
(2001)
Haematologica
, vol.86
, pp. 399-403
-
-
Palumbo, A.1
Giaccone, L.2
Bertola, A.3
-
54
-
-
0036336215
-
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia
-
Coleman M, Leonard J, Lyons L, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2002;43:1777-82.
-
(2002)
Leuk Lymphoma
, vol.43
, pp. 1777-1782
-
-
Coleman, M.1
Leonard, J.2
Lyons, L.3
-
55
-
-
41349095820
-
A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group
-
Rajkumar S, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2007;110.
-
(2007)
Blood
, pp. 110
-
-
Rajkumar, S.1
Jacobus, S.2
Callander, N.3
-
56
-
-
48149114717
-
Maintenance treatment in multiple myeloma
-
19(Suppl 4):iv54-5
-
Harousseau JL. Maintenance treatment in multiple myeloma. Ann Oncol. 2008;19(Suppl 4):iv54-5.
-
(2008)
Ann Oncol
-
-
Harousseau, J.L.1
-
57
-
-
0016774995
-
Prognostic factors in multiple myeloma
-
Alexanian R, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer. 1975;36:1192-201.
-
(1975)
Cancer
, vol.36
, pp. 1192-1201
-
-
Alexanian, R.1
Balcerzak, S.2
Bonnet, J.D.3
-
58
-
-
0023870374
-
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients
-
Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988;57:94-9.
-
(1988)
Br J Cancer
, vol.57
, pp. 94-99
-
-
Belch, A.1
Shelley, W.2
Bergsagel, D.3
-
59
-
-
0033637036
-
Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients
-
Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427-36.
-
(2000)
Ann Oncol
, vol.11
, pp. 1427-1436
-
-
Fritz, E.1
Ludwig, H.2
-
60
-
-
20944446210
-
Interferon-alpha as maintenance therapy in patients with multiple myeloma
-
Schaar CG, Kluin-Nelemans HC, Te Marvelde C, et al. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol. 2005;16:634-9.
-
(2005)
Ann Oncol
, vol.16
, pp. 634-639
-
-
Schaar, C.G.1
Kluin-Nelemans, H.C.2
Te Marvelde, C.3
-
61
-
-
0036566201
-
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
-
Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163-8.
-
(2002)
Blood
, vol.99
, pp. 3163-3168
-
-
Berenson, J.R.1
Crowley, J.J.2
Grogan, T.M.3
-
62
-
-
33845899121
-
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7
-
Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol. 2007;136:203-11.
-
(2007)
Br J Haematol
, vol.136
, pp. 203-211
-
-
Shustik, C.1
Belch, A.2
Robinson, S.3
-
63
-
-
33644833147
-
Thalidomide and hematopoietic- cell transplantation for multiple myeloma
-
Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic- cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-30.
-
(2006)
N Engl J Med
, vol.354
, pp. 1021-1030
-
-
Barlogie, B.1
Tricot, G.2
Anaissie, E.3
-
64
-
-
33751164196
-
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
-
Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289-94.
-
(2006)
Blood
, vol.108
, pp. 3289-3294
-
-
Attal, M.1
Harousseau, J.L.2
Leyvraz, S.3
-
65
-
-
36749077596
-
Thalidomide improves survival when used following ASCT
-
92(Suppl 2):S7b.5
-
Spencer A, Prince HM, Roberts A, et al. Thalidomide improves survival when used following ASCT. Haematologica. 2007;92(Suppl 2):S7b.5.
-
(2007)
Haematologica
-
-
Spencer, A.1
Prince, H.M.2
Roberts, A.3
-
66
-
-
41349095233
-
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial
-
Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805-10.
-
(2008)
Blood
, vol.111
, pp. 1805-1810
-
-
Abdelkefi, A.1
Ladeb, S.2
Torjman, L.3
-
67
-
-
65349191004
-
S0204: Melphalan (MEL)-based tandem autotransplants (TAT) for multiple myeloma (MM) with thalidomide/dexamethasone (TD) induction and thalidomide/prednisone (TP) maintenance: A phase II trial of the Southwest Oncology Group
-
Hussein M, Jakubowiak AJ, Bolejack V, et al. S0204: Melphalan (MEL)-based tandem autotransplants (TAT) for multiple myeloma (MM) with thalidomide/dexamethasone (TD) induction and thalidomide/prednisone (TP) maintenance: A phase II trial of the Southwest Oncology Group. Blood. 2006;108.
-
(2006)
Blood
, pp. 108
-
-
Hussein, M.1
Jakubowiak, A.J.2
Bolejack, V.3
-
68
-
-
0242691239
-
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
-
Goldschmidt H, Sonneveld P, Cremer FW, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol. 2003;82:654-9.
-
(2003)
Ann Hematol
, vol.82
, pp. 654-659
-
-
Goldschmidt, H.1
Sonneveld, P.2
Cremer, F.W.3
-
72
-
-
33750700802
-
Treatment for myeloma bone disease
-
Yeh HS, Berenson JR. Treatment for myeloma bone disease. Clin Cancer Res. 2006;12(20 Pt 2):6279s-84s.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.20 PART 2
-
-
Yeh, H.S.1
Berenson, J.R.2
-
73
-
-
36549010158
-
Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates
-
Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022-33.
-
(2007)
J Dent Res
, vol.86
, pp. 1022-1033
-
-
Kimmel, D.B.1
-
74
-
-
36549072502
-
Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy
-
Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-57.
-
(2007)
Ann N Y Acad Sci
, vol.1117
, pp. 209-257
-
-
Russell, R.G.1
Xia, Z.2
Dunford, J.E.3
-
75
-
-
10744233717
-
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: Results of a randomized trial
-
Musto P, Falcone A, Sanpaolo G, et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma. 2003;44:1545-8.
-
(2003)
Leuk Lymphoma
, vol.44
, pp. 1545-1548
-
-
Musto, P.1
Falcone, A.2
Sanpaolo, G.3
-
76
-
-
10744233021
-
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-44.
-
(2003)
Cancer
, vol.98
, pp. 1735-1744
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
78
-
-
6844252283
-
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group
-
Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
-
(1998)
J Clin Oncol
, vol.16
, pp. 593-602
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
79
-
-
33644841755
-
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
-
Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-7.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8580-8587
-
-
Bamias, A.1
Kastritis, E.2
Bamia, C.3
-
80
-
-
21444449880
-
Osteonecrosis of the jaw and bisphosphonates
-
Discussion 199-202
-
Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102; Discussion 199-202.
-
(2005)
N Engl J Med
, vol.353
, pp. 99-102
-
-
Durie, B.G.1
Katz, M.2
Crowley, J.3
-
81
-
-
33745792743
-
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid
-
Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968-71.
-
(2006)
Haematologica
, vol.91
, pp. 968-971
-
-
Dimopoulos, M.A.1
Kastritis, E.2
Anagnostopoulos, A.3
-
82
-
-
33746855407
-
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
-
Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-53.
-
(2006)
Mayo Clin Proc
, vol.81
, pp. 1047-1053
-
-
Lacy, M.Q.1
Dispenzieri, A.2
Gertz, M.A.3
-
83
-
-
34347260332
-
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
-
Kyle RA, Yee GC. Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007; 25:2464-72.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2464-2472
-
-
Kyle, R.A.1
Yee, G.C.2
Somerfield, M.R.3
-
84
-
-
0030012115
-
Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma
-
Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood. 1996;87:2675-82.
-
(1996)
Blood
, vol.87
, pp. 2675-2682
-
-
Osterborg, A.1
Boogaerts, M.A.2
Cimino, R.3
-
85
-
-
33846339172
-
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
-
Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258-70.
-
(2007)
Eur J Cancer
, vol.43
, pp. 258-270
-
-
Bokemeyer, C.1
Aapro, M.S.2
Courdi, A.3
-
86
-
-
33646494190
-
Lenalidomide and venous thrombosis in multiple myeloma
-
Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079-80.
-
(2006)
N Engl J Med
, vol.354
, pp. 2079-2080
-
-
Knight, R.1
DeLap, R.J.2
Zeldis, J.B.3
-
87
-
-
41149161749
-
Thromboembolic events with lenalidomide-based therapy for multiple myeloma
-
Menon SP, Rajkumar SV, Lacy M, et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer. 2008;112:1522-8.
-
(2008)
Cancer
, vol.112
, pp. 1522-1528
-
-
Menon, S.P.1
Rajkumar, S.V.2
Lacy, M.3
|